GlassScriptPhysician profile
Umakantha E Sannesy
NPI 1508810664
$3,709.30
in general payments reported to CMS, 2019-2025
11 companies · $1,341 in 2025
The $1,341 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2021: $255 · 2022: $123 · 2023: $975 · 2024: $252 · 2025: $1,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,568.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $894.75 | 2019-2025 | Austedo, Uzedy |
| Abbvie INC. | $499.78 | 2022-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $447.36 | 2019-2024 | Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $362.76 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $356.14 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.38 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $247.01 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $240.37 | 2025 | Auvelity |
| Impulse Dynamics (USA) INC. | $159.90 | 2023 | Optimizer |
| Novo Nordisk INC | $125.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $123.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umakantha Sannesy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.